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Abstract
Background: Cannabis therapy has been considered an effective treatment for spasticity, although
clinical reports of symptom reduction in multiple sclerosis (MS) describe mixed outcomes.
Recently introduced therapies of combined Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
extracts have potential for symptom relief with the possibility of reducing intoxication and other
side effects. Although several past reviews have suggested that cannabinoid therapy provides a
therapeutic benefit for symptoms of MS, none have presented a methodical investigation of newer
cannabinoid treatments in MS-related spasticity. The purpose of the present review was to
systematically evaluate the effectiveness of combined THC and CBD extracts on MS-related
spasticity in order to increase understanding of the treatment's potential effectiveness, safety and
limitations.
Methods:  We reviewed MEDLINE/PubMed, Ovid, and CENTRAL electronic databases for
relevant studies using randomized controlled trials. Studies were included only if a combination of
THC and CBD extracts was used, and if pre- and post-treatment assessments of spasticity were
reported.
Results: Six studies were systematically reviewed for treatment dosage and duration, objective
and subjective measures of spasticity, and reports of adverse events. Although there was variation
in the outcome measures reported in these studies, a trend of reduced spasticity in treated patients
was noted. Adverse events were reported in each study, however combined TCH and CBD
extracts were generally considered to be well-tolerated.
Conclusion: We found evidence that combined THC and CBD extracts may provide therapeutic
benefit for MS spasticity symptoms. Although some objective measures of spasticity noted
improvement trends, there were no changes found to be significant in post-treatment assessments.
However, subjective assessment of symptom relief did often show significant improvement post-
treatment. Differences in assessment measures, reports of adverse events, and dosage levels are
discussed.
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Background
Spasticity, an involuntary increase in muscle tone or rapid
muscle contractions, is one of the more common and dis-
tressing symptoms of multiple sclerosis (MS). Medicinal
treatment may reduce spasticity, but may also be ineffec-
tive, difficult to obtain, or associated with intolerable side
effects [1,2]. Cannabis, a psychotropic drug known for its
analgesic properties, also has a long history as an effective
and tolerable treatment for spasticity [3,4]. Demographic
evidence has shown that many people with MS use canna-
bis for symptom management [5].
Clinical studies, animal models, and anecdotal reports [6-
8] have suggested that cannabis may be an effective treat-
ment of MS spasticity. The antispastic effect of cannabis
has been supported through a demonstration of the
inhibitory properties in exogenous agonists for cannabis
receptors found in the CNS [7]. Early clinical trials report-
ing the efficacy and safety of cannabis use in MS have
focused on the effects of Δ9-tetrahydrocannabinol (THC).
Although these clinical studies reported a therapeutic ben-
efit for MS symptoms, there were concerns of potential
intoxication and other side effects of cannabis-based treat-
ment [9]. Another clinical study using a cannabidiol
(CBD) extract documented a reduction in spasticity-
related pain but not in spasticity [10].
More recent combination therapies using whole plant
extracts of both THC and CBD have been introduced and
there is evidence that CBD, which is not psychotropic,
may reduce THC levels in the brain and attenuate its psy-
chotropic side effects [11-14]. Such therapies may poten-
tially provide a tolerable yet effective treatment for MS
symptoms [3]. A number of recent studies [15-22] have
investigated the potential efficacy and safety of whole
plant extracts of THC and CBD. One of the first large-scale
studies of cannabis treatment for MS-related spasticity
compared whole plant cannabis extracts with THC and a
placebo, and found mixed evidence for the therapeutic
benefit of spasticity in MS. A recent review [23] that
included a number of these recent studies provided addi-
tional support for the benefit of cannabinoids in MS-
related spasticity but called for further study into long-
term treatment and side effects. A systematic evaluation of
recent research had not previously been conducted, and
was needed in order to provide organized evidence of can-
nabinoid treatments and direction for future clinical stud-
ies. We therefore systematically reviewed studies that used
a combination extract of THC and CBD for the treatment
of spasticity.
Methods
Searching
We conducted a comprehensive search using MEDLINE/
PubMed, Ovid, and CENTRAL (Cochrane Central Register
of Controlled Trials) for English-language only literature
published from 1999 to April 2009 using different combi-
nations of the following MeSH and free text terms: canna-
bis, cannabinoid, THC, CBD, multiple sclerosis,
spasticity, spasms. Reference lists from retrieved reports
were reviewed for additional studies. Unpublished data
were not sought and abstracts, letters, case reports, and
review articles were excluded. (See Additional file 1 for a
Quality of Reporting of Meta-analyses (QUOROM) state-
ment checklist.)
Selection and quality assessment
Only randomized, placebo-controlled, human studies of
shorter treatment periods (under 6 months) were
included. Studies were evaluated for methodological
quality using Jadad scores [24] and only studies with
Jadad scores of 4 or higher were considered for inclusion.
Relevant trials included those that had administered a
combination THC and CBD extract, those in which clini-
cally stable spasticity had been established prior to trial
and those that reported objective measures of pre- and
post-treatment spasticity. Studies that used active control
groups were not excluded. Abstracts were reviewed for rel-
evancy and full text versions of potentially relevant rand-
omized controlled studies were reviewed. Reports not
considered relevant were excluded and all included
reports were read in entirety.
Data abstraction
Data were extracted independently by the authors and any
disagreements were resolved by consensus. The following
information was extracted from each report: study type,
study objective, sample size, controls, type and amount of
cannabinoid used, treatment duration, objective and sub-
jective outcome measures, and reported adverse events.
Analysis
A qualitative summary of the data was completed to com-
pare the various outcome measures used across the
included studies. In addition, a quantitative analysis of
the one common outcome measure (Ashworth scale)
used by the included studies was performed in order to
assess statistical heterogeneity.
Results
Flow of included studies
Electronic searches found 38 studies that were potentially
relevant to the present review. Of these, 33 did not meet
the inclusion/exclusion criteria, including 27 reports that
were not randomized, controlled trials. One study was
excluded for focusing on spasticity-related pain and two
were excluded for not assessing the effects of a combined
extract of THC and CBD. Two studies were excluded for
reporting long-term follow-up data (see Figure 1).BMC Neurology 2009, 9:59 http://www.biomedcentral.com/1471-2377/9/59
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Study characteristics
Six double-blind, randomized, placebo-controlled trials
published between 2002 and 2007 were analyzed [15-
20]. These studies included a total of 481 patients with MS
who were administered a combined extract of both THC
and CBD. Three trials used a crossover design. Three trials
used a parallel design in which 339 patients were admin-
istered a placebo only. Trial periods ranged from 2 to 15
weeks. Objective spasticity measures were extracted when
included in the assessment data from at least two studies.
All six trials reported an adjusted mean change score in
the Ashworth scale assessment. Other measures of spastic-
ity included mean changes from a baseline score in the
following assessments: Visual Analogue Scale (VAS), a rat-
ing scale to measure the severity of spasticity; walk time;
Rivermead Mobility Index (RMI), a measure of disability
related to mobility; and self-reported ratings of spasm fre-
quency or severity. (See Table 1 for the specific character-
istics of each reviewed study.)
Qualitative analysis
Overall reduction of spasticity
Five studies [16-20] concluded that cannabis extract may
decrease spasticity and improve mobility in patients with
MS. One study [15] reported no reduction in spasticity.
Adverse effects were reported in each study; however side
effects from combined extracts of THC and CBD were gen-
erally well-tolerated. Two blinded studies comparing
combined extracts of THC and CBD to extracts of THC
alone found a lower incidence of adverse events in the
combined THC and CBD trials [16,17], and one study
found a higher incidence of adverse events [15]. In all
three comparison studies, there was no distinction in effi-
cacy between THC extracts and combined THC and CBD
extracts.
Ashworth score
In one study [18], 50 patients were assessed with the Ash-
worth scale for muscle tone and showed significant
improvement during the active treatment trial. The other
five studies reported little to no improvement in their ver-
sions of the Ashworth scale. It should be noted that the
Ashworth scale is subject to individual assessor evaluation
and there may have been variation between studies in the
modification of scale measures.
Visual Analogue Scale
Three studies reported data from VAS scores [15,17,19].
Two studies reported that patients on active treatment
showed a significant improvement in VAS scores [17,19],
and one reported no significant difference [15]. In one
study [17], daily recorded assessment data from 14 MS
patients were mixed with data from six patients with other
neurological disorders. The other studies recorded daily
[15] or weekly [19] assessments.
Walk time
Although five studies included walk time in their pro-
posed assessments, only two studies [16,19] reported data
from 160 patients with MS. Although both showed a
trend for improvement in walk time, P-value did not reach
statistical significance in one study [19] and was not
reported in the other [16].
Rivermead Mobility Index
Three studies [16-18] reported RMI scores for 275 MS
patients. Although there was a trend for improvement
from baseline to study completion, mean changes in
assessment were significant in one study [18] and insignif-
icant in the other two studies.
Other subjective rating scales
All six studies reported an additional measure of subjec-
tive assessment. Rating scales were completed by a total of
379 patients in order to record various changes in spastic-
ity throughout the trials. Five studies [16-20] reported sig-
nificant improvements in spasticity as subjectively rated
by patients with MS and one reported deterioration [15].
Flow diagram of included studies Figure 1
Flow diagram of included studies.BMC Neurology 2009, 9:59 http://www.biomedcentral.com/1471-2377/9/59
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Table 1: Analysis of six randomized controlled trials reporting measures of spasticity after THC-CBD treatment
Killestein 2002 [15] Wade 2003 [17] Zajicek 2003 [16] Wade 2004 [19] Vaney 2004 [18] Collin 2007 [20]
Design Crossover Crossover Parallel Parallel Crossover Parallel
Jaded score 44 5 5 5 4
Study objective Small study to 
compare effects of 
THC and THC-CBD
Pilot study to 
explore benefits 
for neurogenic 
symptoms
Large study to 
compare effects of 
THC and THC-
CBD
Benefits over a 
range of 
symptoms
Effects on spasm 
frequency
Effects on 
spasticity
Sample size 16 14 395 (198 placebo) 154 (77 placebo) 57 184 (64 placebo)
Duration 4 weeks 4 weeks 15 weeks 6 weeks 2 weeks 6 weeks
Intervention THC-CBD
<10 mg daily
THC-CBD
2.5-120 mg daily
THC-CBD
<25 mg daily
THC-CBD
<120 mg daily
THC-CBD
<30 mg daily
THC-CBD
>25 mg daily
Ashworth score
Mean change App. -.3 No change 1.24 -0.37 -2.2 -0.64
P-value Not significant >0.05 0.29 0.22 0.002 0.218
VAS spasticity Not reported Not reported Not reported
Mean change No change Reduced 14.9 
points
Reduced 31.2 
points
P-value Not significant <0.05 0.001
Walk time Not reported Not reported Not reported Not reported
Mean change Reduced 4% Reduced 2.78 (s)
P-value Not reported 0.07
RMI Not reported Not reported Not reported
Mean change Improved 0.2 Improved 0.4 Improved 0.5
P-value >0.05 0.21 0.005
Self-reported 
rating
Measure Global impression 
VAS
Numerical 
symptom scale
Category rating 
scale
Diary entry VAS 
scale
Spasm frequency 
scale
Numerical rating 
scale
Mean change Worsened Frequency 
reduced 1.9; 
severity reduced 
2.1
52% treated 
reported 
improvement
Frequency score 
reduced 21.41; 
severity reduced 
21.67
Reduced 0.4 Reduced 1.18
P-value 0.02 <0.05 0.01 0.009 <0.001 0.048
Adverse events 41 reported, none 
serious
16 reported 12 serious 
reported
4% withdrawn No serious 
reported
4.8% withdrawn
RMI, Rivermead Mobility Index; VAS, Visual Analogue Scale.BMC Neurology 2009, 9:59 http://www.biomedcentral.com/1471-2377/9/59
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Meta-analysis
Three of the studies [15,19,20] did not report adequate
(mean and standard deviation) Ashworth scale data for
inclusion in the quantitative meta-analysis. This left three
studies for the calculation of the pooled mean difference
in Ashworth scores. The chi-square test for heterogeneity
showed evidence of significant variation between the
three studies (χ2 = 5.25, P = .07, l2 = 62%). Given that only
three of the six studies reported adequate Ashworth scale
data [16-18], of these three only one demonstrated statis-
tically significant findings [18], and the high level of het-
erogeneity, a quantitative analysis of the data was deemed
inappropriate.
Discussion
Limitations
There were some limitations to the systematic review.
First, this review did not include unpublished data. There
may be ongoing clinical trials of combination THC and
CBD therapy as it is a relatively recent therapy. There is
also the possibility that other clinical reports using whole
plant cannabis extracts may have been appropriate for
review, but were not included without report of specific
methodology. A meta-analytical review of the effects of
cannabis on spasticity would be useful, but was not
deemed appropriate for the present review because of the
variation in assessment data.
Subjective vs. objective measures
The validity of the Ashworth scale as an outcome measure
has been previously questioned [16]. However, we have
shown that other objective measures of spasticity (i.e.
RMI, walk time) may also fail to adequately support the
improvements found in scores from more subjective
measures (i.e. rating scales, diary entries). A long-term fol-
low-up study [21] showed a significant improvement in
the Ashworth scale, however, the change was still small
and was found in the THC group only. Another concern is
that participants of both active and placebo trials may not
be entirely blind to their treatment status [16], and this
may affect subjective assessments. It remains that, without
a validated, objective measure of spasticity, it will be diffi-
cult to accurately measure the effects of cannabis therapy
on MS spasticity.
Adverse events
Adverse effects were reported in each trial in which
patients received active treatment (including THC-only
treatment). There is some evidence that combined extracts
of THC and CBD may attenuate side effects of THC alone,
and future studies are needed to compare the safety of
combined cannabis extracts with traditional treatment.
Dosage is another concern that should be considered in
the context of side effects. Incidence of side effects varies
greatly depending on the amount of cannabis needed to
effectively limit spasticity. In one study [17], it was noted
that the initially permitted dosage level sometimes
resulted in marked side effects, and the dosage was there-
after reduced. The careful monitoring of symptom relief
and side effects is critical in reaching an individual's opti-
mal dose. Finally, it should be noted that several adverse
events were also reported in each trial in which patients
received a placebo. In a long-term follow-up [22] of one
of the reviewed studies [19], it was determined that most
of the reported adverse events were unrelated to cannabis
treatment. Considering the distress and limitations spas-
ticity brings to individuals with MS, it would be important
to carefully weigh the potential for side effects with the
potential for symptom relief, especially in view of the
relief reported in subjective assessment.
Conclusion
We found evidence that combined extracts of THC and
CBD may reduce symptoms of spasticity in patients with
MS. Although the subjective experience of symptom
reduction was generally found to be significant, objective
measures of spasticity failed to provide significant
changes. In a previous study of spasticity-related pain, MS
patients also reported a subjective perception of symptom
reduction with cannabinoids [10]. However, since at least
one past animal study has provided objective, physiolog-
ical evidence for the antispastic properties of cannabi-
noids [7], the distinction between perceived symptom
relief and objective physiological changes in humans
should therefore be primary in future research efforts.
Given that adverse events occurred in each reviewed trial,
we also encourage future comparison studies of cannabis
treatments at a wide range of dosage in order to balance
potential side effects with maximum therapeutic benefit.
Finally, there is evidence that cannabinoids may provide
neuroprotective and anti-inflammatory benefits in MS.
Neuroinflammation, found in autoimmune diseases such
as MS, has been shown to be reduced by cannabinoids
through the regulation of cytokine levels in microglial
cells [25]. The therapeutic potential of cannabinoids in
MS is therefore comprehensive and should be given con-
siderable attention.
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